undamentalytics Newsletter
Sign in

Cbdmd, Inc. (YCBD) stock

Add to watchlist

Add holding +

NYSE: YCBD NYSE Personal Care Products

C Fundamentals grade

Cbdmd, Inc. is a US-listed company in the personal care products industry. Its financial year ends in September.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$0.9

Price-to-sales vs peers

Base case. Range ~$0.7–$4.5. Sales per share times peers' typical price-to-sales; used only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Cbdmd, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 1 selling0 purchases and 3 sales by directors and officers, last 12 monthsInsider trades
  • Funds8 adding, 8 cuttingOf 1 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Cbdmd files

Where Cbdmd stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $21m, up 10.0% on a year earlier, faster than the 2.0% growth a quarter earlier. That growth ranks 4 of 17 among the personal care products companies we cover. Free-cash-flow margin fell to -11.5% from -6.5% a year earlier. Operating margin narrowed to -13.9% from -9.4%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 2 financial-health checks. Our price-to-sales vs peers value is $1.07 a share, against a share price of $0.39.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Cbdmd, Inc.'s trailing-twelve-month revenue grew 10.0% year on year, with a free-cash-flow margin of -11.5%. Where it stands out: change in growth rate of +8.0pp ranks 2 of 21 personal care products companies we cover. Where it lags: operating margin of -13.9% ranks 21 of 21 personal care products companies we cover.

Current signal Revenue growth accelerating: TTM revenue growth rose to 10.0% (+8.0pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Growth speeding up. The growth rate is 8.0 points higher than a quarter earlier.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Loss-making. Operating margin is -13.9%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 4.4 points on a year ago.
  • Burning cash. Free cash flow was -11.5% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 149% and a beta of 0.3 against the S&P 500.
  • Gross margin slipping. Gross margin is down 3.5 points on a year ago.

Latest results: FY2026 Q3

Filed August 13, 2026
Earnings per share
-$0.11 against an average estimate of -$0.03: missed by 266.7%
Revenue
$6m, up 20.6% on a year earlier

Cbdmd's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+7.2%
  • 1 week+15.1%
  • 1 month-6.6%
  • This year-70.6%
  • 1 year-49.4%
  • 5 years-99.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$20.9M
Operating margin
-13.9%
Net margin
-13.8%

Growth

Revenue growth
+10.0%
Change in growth rate
+8.0 pts

Cash

Free cash flow (TTM)
-$2.4M
FCF margin
-11.5%

Earnings

Last results
November 25, 2025

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Cbdmd, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Cbdmd, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 7.4%: the 10-year Treasury yield (4.9%) plus a beta of 0.55 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.9 ~$0.7–$4.5 Included, half weight
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$0.9 ~$0.7–$4.5 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Cbdmd, Inc. with Personal Care Products in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20182019202020212022202320242025
Share price$1306.80$1425.60$720.00$748.80$81.00$8.28$3.76$1.21
Market value$28m$71m$90m$114m$13m$2m$2m$5m
+ Net debt (− = net cash)−$4m−$5m−$15m−$26m−$7m−$2m$96755−$2m
Enterprise value$24m$66m$76m$88m$7m$297742$2m$3m
Multiples
Price / sales 61.3x3.0x2.2x2.6x0.4x0.1x0.1x0.3x
Price / earnings n/m—7.2x—————
Price / free cash flow ————————
EV / EBITDA ————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

30 /100

Weak moat

How hard Cbdmd's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -23.0% of total assets over 9 years.

  • Pricing power 18 / 20

    Gross margin has been a median 62.3%, moving by 3.8 percentage points (standard deviation) across 9 years.

  • Durability 10 / 20

    Operating margin has been a median -46.0%; its worst year was -188.3%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 9 years, at a median -24.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (35 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.33 +70% $22m +14%
Next −$0.19 +42% $29m +30%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +73.7% on 90 days ago. In the last 30 days, 0 analysts raised Cbdmd, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Cbdmd, Inc., last 90 days
−$0.40 −$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.19 Current fiscal year, 60 days ago: −$0.19 Current fiscal year, 30 days ago: −$0.19 Current fiscal year, 7 days ago: −$0.33 Current fiscal year, Now: −$0.33 −$0.33 Next fiscal year, 90 days ago: −$0.07 Next fiscal year, 60 days ago: −$0.07 Next fiscal year, 30 days ago: −$0.07 Next fiscal year, 7 days ago: −$0.37 Next fiscal year, Now: −$0.19 −$0.19

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.19−$0.07
60 days ago −$0.19−$0.07
30 days ago −$0.19−$0.07
7 days ago −$0.33−$0.37
Now −$0.33−$0.19

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.03 −$0.11 −266.7%
Mar 2026 −$0.05 −$0.08 −60.0%
Dec 2025 −$0.06 −$0.04 +33.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

1 analysts, Oct 2026
Buy00%
Hold1100%
Sell00%

Monthly trend

  1. Oct 202611
  2. Sep 202611

Counts of recommendations published by analysts covering Cbdmd, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
5.2%
of tradable shares
Days to cover
0.68
at average volume
Short interest, 1 month
+7%
to October 15, 2026
Held by institutions
8%
of shares
Held by insiders
10.0%
of shares
Employees
42
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
YCBD−63%−79%−90%−64%−55%−71%
Industry peers (median)+32%−32%+6%−8%−34%+1%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
YCBD25%33%33%25%33%18%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
YCBD−84%−82%−96%−69%−90%−74%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 17, 2017: 100% from May 10, 2019 to October 19, 2026. Getting back needed a 700245% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.35 – $2.27
From 52-week high
−82.5%
vs 50-day average
−9.1%
vs 200-day average
−40.1%
Volatility (1 year)
149%
Beta vs S&P 500
0.30

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 6 down
typical move ±6.9%
After a week
6 up, 5 down
typical move ±7.9%
After a month
5 up, 6 down
typical move ±28.7%
Results releasedNext dayS&P 500 next day5 days21 days
November 25, 2025 +2.1% +1.6% +13.0% +220.0%
August 12, 2021 −5.0% +0.5% −7.3% −0.9%
May 12, 2021 −21.8% −0.9% −14.5% −1.2%
December 2, 2020 +3.6% +0.2% 0.0% −2.9%
October 27, 2020 −4.2% −3.8% +0.5% +19.0%
October 14, 2020 −2.6% −0.8% +0.9% +7.9%
August 4, 2020 +8.1% +1.0% +6.9% −24.3%
April 6, 2020 −0.7% +6.8% +14.2% +21.8%
May 10, 2019 +6.0% −2.0% +1.8% −1.8%
February 15, 2019 +8.4% +1.3% −6.4% −9.4%
December 13, 2018 −13.6% −1.9% −21.5% +6.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Cbdmd, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Cbdmd, Inc.
$18M $20M $22M $24M $26M FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $24.2M Revenue (TTM), FY24 Q1: $23.4M Revenue (TTM), FY24 Q2: $21.6M Revenue (TTM), FY24 Q3: $20.6M Revenue (TTM), FY24 Q4: $19.5M Revenue (TTM), FY25 Q1: $19.2M Revenue (TTM), FY25 Q2: $19.6M Revenue (TTM), FY25 Q3: $19M Revenue (TTM), FY25 Q4: $19.2M Revenue (TTM), FY26 Q1: $19.1M Revenue (TTM), FY26 Q2: $20M Revenue (TTM), FY26 Q3: $20.9M $20.9M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $24.2M
FY24 Q1 $23.4M
FY24 Q2 $21.6M
FY24 Q3 $20.6M
FY24 Q4 $19.5M
FY25 Q1 $19.2M
FY25 Q2 $19.6M
FY25 Q3 $19M
FY25 Q4 $19.2M
FY26 Q1 $19.1M
FY26 Q2 $20M
FY26 Q3 $20.9M
Revenue growth, TTM YoY Cbdmd, Inc.
-40% -20% 0% 20% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: -31.8% Revenue growth, TTM YoY, FY24 Q1: -27.1% Revenue growth, TTM YoY, FY24 Q2: -25.0% Revenue growth, TTM YoY, FY24 Q3: -21.5% Revenue growth, TTM YoY, FY24 Q4: -19.3% Revenue growth, TTM YoY, FY25 Q1: -18.0% Revenue growth, TTM YoY, FY25 Q2: -9.2% Revenue growth, TTM YoY, FY25 Q3: -7.8% Revenue growth, TTM YoY, FY25 Q4: -1.5% Revenue growth, TTM YoY, FY26 Q1: -0.7% Revenue growth, TTM YoY, FY26 Q2: 2.0% Revenue growth, TTM YoY, FY26 Q3: 10.0% 10.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 -31.8%
FY24 Q1 -27.1%
FY24 Q2 -25.0%
FY24 Q3 -21.5%
FY24 Q4 -19.3%
FY25 Q1 -18.0%
FY25 Q2 -9.2%
FY25 Q3 -7.8%
FY25 Q4 -1.5%
FY26 Q1 -0.7%
FY26 Q2 2.0%
FY26 Q3 10.0%
Operating margin (TTM) Cbdmd, Inc.
-100% -50% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: -93.1% Operating margin (TTM), FY24 Q1: -83.2% Operating margin (TTM), FY24 Q2: -91.1% Operating margin (TTM), FY24 Q3: -88.3% Operating margin (TTM), FY24 Q4: -17.0% Operating margin (TTM), FY25 Q1: -12.2% Operating margin (TTM), FY25 Q2: -6.5% Operating margin (TTM), FY25 Q3: -9.4% Operating margin (TTM), FY25 Q4: -11.3% Operating margin (TTM), FY26 Q1: -12.4% Operating margin (TTM), FY26 Q2: -13.4% Operating margin (TTM), FY26 Q3: -13.9% -13.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -93.1%
FY24 Q1 -83.2%
FY24 Q2 -91.1%
FY24 Q3 -88.3%
FY24 Q4 -17.0%
FY25 Q1 -12.2%
FY25 Q2 -6.5%
FY25 Q3 -9.4%
FY25 Q4 -11.3%
FY26 Q1 -12.4%
FY26 Q2 -13.4%
FY26 Q3 -13.9%
FCF margin (TTM) Cbdmd, Inc.
-20% -15% -10% -5% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: -19.0% FCF margin (TTM), FY24 Q1: -11.3% FCF margin (TTM), FY24 Q2: -8.0% FCF margin (TTM), FY24 Q3: -5.3% FCF margin (TTM), FY24 Q4: -2.8% FCF margin (TTM), FY25 Q1: -3.8% FCF margin (TTM), FY25 Q2: -1.2% FCF margin (TTM), FY25 Q3: -6.5% FCF margin (TTM), FY25 Q4: -8.5% FCF margin (TTM), FY26 Q1: -11.2% FCF margin (TTM), FY26 Q2: -13.3% FCF margin (TTM), FY26 Q3: -11.5% -11.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -19.0%
FY24 Q1 -11.3%
FY24 Q2 -8.0%
FY24 Q3 -5.3%
FY24 Q4 -2.8%
FY25 Q1 -3.8%
FY25 Q2 -1.2%
FY25 Q3 -6.5%
FY25 Q4 -8.5%
FY26 Q1 -11.2%
FY26 Q2 -13.3%
FY26 Q3 -11.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2016 Sept 2016 2017 Sept 2017 2018 Sept 2018 2019 Sept 2019 2020 Sept 2020 2021 Sept 2021 2022 Sept 2022 2023 Sept 2023 2024 Sept 2024 2025 Sept 2025 LTM Jun 2026
Income
Revenue 2 4 0 24 42 44 35 24 19 19 21
Gross profit 0 3 0 15 26 30 22 15 12 12 12
EBITDA −4 −1 −2 −15 −17 −19 −77 −22 −3 −2 −3
Operating income −4 −1 −2 −15 −18 −20 −78 −22 −3 −2 −3
Net income −4 −1 0 −51 13 −23 −70 −23 −4 −2 −3
Diluted EPS −$406.80 −$136.80 $0.00 $0.00 $100.80 −$0.47 −$446.40 −$106.56 −$14.29 −$1.09 —
Growth (year on year)
Revenue — +120.3% −89.7% +>999% +77.1% +6.2% −20.4% −31.8% −19.3% −1.5% +10.0%
Net income — — — <−999% — −285.6% — — — — —
Diluted EPS — — — — — −100.5% — — — — —
Margins
Gross margin 20.3% 69.7% 77.3% 61.4% 63.0% 67.4% 63.1% 62.0% 61.6% 62.4% 57.7%
EBITDA margin −189.2% −28.8% −343.0% −61.3% −40.3% −41.8% −218.4% −91.4% −14.7% −9.4% −12.8%
Operating margin −191.4% −30.4% −391.4% −62.6% −42.0% −44.1% −221.1% −93.1% −17.0% −11.3% −13.9%
Net margin −191.8% −31.0% 13.7% −217.1% 30.1% −52.6% −198.0% −95.0% −19.0% −10.6% −13.8%
Free-cash-flow margin −148.9% −52.2% <−999% −70.1% −28.6% −32.5% −44.2% −19.0% −2.8% −8.5% −11.5%
Cash flow
Cash from operations −3 −2 −6 −15 −11 −14 −15 −4 −0 −1 −2
Capital spending 0 0 0 1 1 0 1 0 0 0 0
Free cash flow −3 −2 −6 −17 −12 −14 −16 −5 −1 −2 −2
Stock-based pay 0 0 1 2 2 1 — — — — —
Free cash flow after stock pay −3 −2 −6 −19 −14 −16 — — — — —
Balance sheet
Cash 0 0 4 5 15 26 7 2 2 2 2
Total debt 1 0 0 0 0 0 0 0 3 0 0
Net debt (negative = net cash) 1 −0 −4 −5 −15 −26 −7 −2 0 −2 −2
Diluted shares — 13m — — — — — — — 4m —
Returned to shareholders
Dividends — — — 0 0 3 — — — — —
Total returned — — — 0 0 3 — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $13m
Short-term assets $8mLonger-term assets $5m
What it owes, and who funded it · $13m
Short-term liabilities $3mLonger-term liabilities $2mShareholders' equity $8m
  • Short-term assets cover short-term liabilities $8m of assets due within a year against $3m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $8m short-term assets against $2m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Cbdmd, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Days sales outstanding
16 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in personal care products
Last 12 months unless stated YCBD AXIL NHTC FTLF UG MTEX Median
Revenue, last 12 months $21m $30m $34m $36m $11m $107m $913m
Revenue growth, last 12 months 10.0% 10.3% −16.5% −43.3% 3.2% −5.0% 3.5%
Revenue growth, 3-year average −7.3% −5.7% −9.1% −3.0% 2.5% −7.7% −0.1%
Revenue growth, latest quarter 20.6% −11.2% −20.2% 64.6% 9.5% 3.8% 2.7%
Gross margin 57.7% 72.4% 74.3% 34.8% 46.9% 76.1% 69.2%
Operating margin −13.9% 10.0% −5.9% 10.9% 20.8% 2.5% 6.7%
Operating margin, 3-year average −37.2% 6.9% −4.1% 16.0% 25.5% 0.4% 5.5%
Net margin −13.8% 9.3% −4.2% 5.4% 22.0% −6.9% 3.4%
Cash from operations / revenue −10.6% 14.9% −12.3% 28.1% 30.9% 2.3% 9.9%
Free-cash-flow margin −11.5% 14.5% −13.7% 28.0% 30.3% 1.5% 9.6%
Free-cash-flow margin, 3-year average −7.8% 7.1% −11.4% 17.7% 26.4% −1.0% 6.0%
Stock pay / revenue 4.2% 4.3% 0.1% 0.1% — 0.4% 1.0%
Change in share count — −5.5% −15.7% 0.5% 0.0% 1.2% −0.0%

Median of all 21 companies we cover in personal care products. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

21 personal care products companies
Measure Company Peer median Rank
Revenue growth Growth 10.0% 3.5% 5 of 21
Change in growth rate Growth +8.0pp +0.7pp 2 of 21
Gross margin Profitability 57.7% 69.2% 15 of 21
Operating margin Profitability -13.9% 6.7% 21 of 21
Net margin Profitability -13.8% 3.4% 20 of 21
Free-cash-flow margin Cash generation -11.5% 9.6% 20 of 21
Days sales outstanding Balance sheet 16 days 33 days 5 of 14

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$611,735
Institutions reporting
27
Shares held vs prior quarter
▼ 2.5%
Positions opened / closed
6 / 4

Top buyers and sellers, Q2 2026: 8 institutions bought and 8 sold ; the biggest buyer was Vanguard Capital Management LLC (+69K shares) and the biggest seller UBS Group AG (−143K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Worth Venture Partners, LLC $124,368 185K 20.3% 0.0%
Css LLC $92,619 138K 15.1% 0.0%
Vanguard Capital Management LLC $80,521 120K 13.2% ▲ 134.4%
Chapin Davis, Inc. $54,681 81K 8.9% 0.0%
Alesco Advisors, LLC, An Esl Co $46,109 69K 7.5% 0.0%
Chicago Partners Investment Group LLC $45,008 78K 7.4% ▲ 478.5%
Xtx Topco Ltd $42,226 63K 6.9% ▼ 31.8%
Jane Street Group, LLC $36,612 54K 6.0% ▼ 28.7%
Vanguard Fiduciary Trust Co $31,737 47K 5.2% 0.0%
UBS Group AG $14,520 22K 2.4% ▼ 86.9%
Commonwealth Equity Services, LLC $10,940 16K 1.8% 0.0%
Stonex Group Inc. $10,309 13K 1.7% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Cbdmd, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $1.3M 3 trades by 1 insider · 0% under pre-set plans
Net ▼ $1.3M net selling
Insider Date Trade Shares Price Value
Crosnoe Clark R. 10% owner December 17, 2025 Sell 461,725 $2.31 $1.1M
Crosnoe Clark R. 10% owner December 17, 2025 Sell 19,101 $2.34 $44,696
Crosnoe Clark R. 10% owner December 17, 2025 Sell 69,875 $2.34 $163,508

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around March 11, 2026 estimated from the company's past filing pattern, not announced

  • November 25, 2025
  • August 12, 2021
  • May 12, 2021
  • December 2, 2020
  • October 27, 2020
  • October 14, 2020

Recent SEC filings

Data status

When each part of this page on Cbdmd, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Cbdmd, Inc. in brief

What does Cbdmd, Inc. do?
Cbdmd, Inc. is a US-listed company in the personal care products industry. Its financial year ends in September.
What is Cbdmd, Inc.'s stock ticker?
Cbdmd, Inc. trades under the ticker YCBD on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Cbdmd, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Cbdmd, Inc. reported revenue of $20.9M, 10.0% higher than a year earlier, according to its SEC filings.
What is Cbdmd, Inc.'s free cash flow?
Cbdmd, Inc.'s free-cash-flow margin is -11.5% of revenue over the trailing twelve months, ranking 20 of the 21 personal care products companies we cover.
Who are Cbdmd, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Worth Venture Partners, LLC, Css LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Cbdmd, Inc.'s market cap?
On September 30, 2025, Cbdmd, Inc.'s market capitalisation was about $4.9M and net debt of -$2.3M. Market figures come from third-party market data and may be delayed.
Who are Cbdmd, Inc.'s competitors?
In our Personal Care Products peer group, the companies closest to Cbdmd, Inc. are Axil Brands, Inc., Natural Health Trends Corp, Fitlife Brands, Inc., United Guardian Inc and Mannatech Inc. The side-by-side comparison below sets their revenue, margins and growth against Cbdmd, Inc.'s.
Are insiders buying or selling Cbdmd, Inc. stock?
Over the last 12 months, Cbdmd, Inc.'s directors and officers reported 0 open-market purchases and 3 sales on Form 4. The insider trading page charts every trade.